FDA Approves Bristol-Myers, AstraZeneca Diabetes Drug

Law360, Washington (January 8, 2014, 4:05 PM EST) -- The U.S. Food and Drug Administration on Wednesday approved a Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP drug designed to treat Type 2 diabetes, about one year after rejecting the same drug due to its potential link to bladder cancer.

The agency said in a news release that it had approved Farxiga, known generically as dapagliflozin, which improves glycemic control with diet and exercise for adults with Type 2 diabetes.

“Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and...
To view the full article, register now.